OBJECTIVE: To assess the impact of donepezil treatment compared with placebo on caregiver time spentassisting patients with Alzheimer's disease (AD). RESEARCH DESIGN AND METHODS: Patient and caregiver data were collected as part of a 1-year, prospective, double-blind, randomized, placebo-controlled trial. The Resource Utilization in Dementia (RUD) questionnaire was used to record caregiver time at study baseline and at Weeks 12, 24, 36, and 52. This analysis focuses solely on those caregivers who were actively (> 0 h/day reported on the RUD) providing care at study baseline. MAIN OUTCOME MEASURES: The change in time relative to baseline that caregivers spent assisting patients over the course of the study. RESULTS: The active caregiver population was composed of 96 caregivers of donepezil-treated patients and 94 caregivers of patients receiving placebo. Over the course of the 1-year study, and as the condition of the AD patients deteriorated, it was expected that caregiver time would increase. As expected, after 52 weeks, caregivers of placebo patients were providing almost 2 h each day (106.8 min) more care than they had done at study baseline. For those caregivers of donepezil-treated patients, although they were spending more time caring than they had done at study baseline, their time burden had only increased by 42.6 min more each day. This difference in caring time between the 2 groups, relative to baseline at Week 52, was 1.1 h (64.2 min) each day, and was significant (p = 0.03). CONCLUSION: Caregiver time devoted to helping an AD patient typically increases with the severity of the disease. By helping the patient maintain his/her ability to perform activities of daily living for longer, treatment with donepezil is not only beneficial to the patient, but also has positive time-burden implications for the caregiver.
RCT Entities:
OBJECTIVE: To assess the impact of donepezil treatment compared with placebo on caregiver time spent assisting patients with Alzheimer's disease (AD). RESEARCH DESIGN AND METHODS: Patient and caregiver data were collected as part of a 1-year, prospective, double-blind, randomized, placebo-controlled trial. The Resource Utilization in Dementia (RUD) questionnaire was used to record caregiver time at study baseline and at Weeks 12, 24, 36, and 52. This analysis focuses solely on those caregivers who were actively (> 0 h/day reported on the RUD) providing care at study baseline. MAIN OUTCOME MEASURES: The change in time relative to baseline that caregivers spent assisting patients over the course of the study. RESULTS: The active caregiver population was composed of 96 caregivers of donepezil-treated patients and 94 caregivers of patients receiving placebo. Over the course of the 1-year study, and as the condition of the ADpatients deteriorated, it was expected that caregiver time would increase. As expected, after 52 weeks, caregivers of placebo patients were providing almost 2 h each day (106.8 min) more care than they had done at study baseline. For those caregivers of donepezil-treated patients, although they were spending more time caring than they had done at study baseline, their time burden had only increased by 42.6 min more each day. This difference in caring time between the 2 groups, relative to baseline at Week 52, was 1.1 h (64.2 min) each day, and was significant (p = 0.03). CONCLUSION: Caregiver time devoted to helping an ADpatient typically increases with the severity of the disease. By helping the patient maintain his/her ability to perform activities of daily living for longer, treatment with donepezil is not only beneficial to the patient, but also has positive time-burden implications for the caregiver.
Authors: A Gustavsson; L Jonsson; T Rapp; E Reynish; P J Ousset; S Andrieu; C Cantet; B Winblad; B Vellas; A Wimo Journal: J Nutr Health Aging Date: 2010-10 Impact factor: 4.075
Authors: George T Grossberg; Daniel D Christensen; Patrick A Griffith; Diana R Kerwin; Gail Hunt; Eric J Hall Journal: Prim Care Companion J Clin Psychiatry Date: 2010
Authors: Mary Sano; Carolyn W Zhu; Peter J Whitehouse; Steven Edland; Shelia Jin; Karin Ernstrom; Ronald G Thomas; Leon J Thal; Steven H Ferris Journal: Alzheimer Dis Assoc Disord Date: 2006 Oct-Dec Impact factor: 2.703